A drug that improves the symptoms of Parkinson's by increasing the amount of a brain chemical called dopamine. Amantadine can reduce the involuntary movements of Parkinson's disease by acting on other brain chemicals as well.

Antiviral compound sometimes used to treat influenza type A infections.

See Amantadine Hydrochloride.

An antiviral agent indicated in adults and children 1 year for the treatment of illness due to influenza and for prophylaxis following exposure to influenza type A viruses. It has no effect against the influenza type B virus.

an antiparkinsonian; prescribed to offset some side effects from psychoactive drugs; brand names include Symmetrel. Amantadine side effects.

A drug which stimulates the release of available dopamine in the brain.

A drug used to treat Parkinson's. See PDS publication The Drug Treatment of Parkinson's Disease (code B13) - 949kb pdf format

Initially developed as an antiviral agent, this drug improves mild tremor, rigidity, and bradykinesia in some patients with PD. The exact mechanism of action is unclear; however, it seems to increase release of dopamine from the remaining cells of the substantia nigra

a medication initially designed to relieve influenza symptoms but later found to assist with rigidity and other parkinsonian symptoms. May also help to reduce dyskinesias.

an anti-Parkinson drug.

(Amantadine hydrochloride) Antiviral agent used to prevent or treat influenza; also used to treat Parkinson's disease.

Amantadine (1-aminoadamantane, sold as Symmetrel®) is an antiviral drug that was approved by the Food and Drug Administration in 1976 for the treatment of Influenzavirus A in adults. The drug has also been demonstrated to help reduce symptoms of Parkinson's disease and drug-induced extrapyramidal syndromes. As an antiparkinsonic it can be used as monotherapy; or together with L-DOPA to treat L-DOPA-related motor fluctuations (i.e., shortening of L-DOPA duration of clinical effect, probably related to progressive neuronal loss) and L-DOPA-related dyskinesias (choreiform movements associated with long-term L-DOPA use, probably related to chronic pulsatile stimulation of dopamine receptors).